$11.64
11.01%
Nasdaq, Jan 02, 10:18 pm CET
ISIN
US9290331084
Symbol
VOR

Vor Biopharma Inc Stock price

$11.64
+4.11 54.58% 1M
-17.36 59.86% 6M
-1.44 11.01% YTD
-10.76 48.04% 1Y
-121.36 91.25% 3Y
-6.36 35.33% 5Y
-6.36 35.33% 10Y
-6.36 35.33% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
-1.44 11.01%
ISIN
US9290331084
Symbol
VOR
Industry

Key metrics

Basic
Market capitalization
$255.0m
Enterprise Value
$84.6m
Net debt
positive
Cash
$170.5m
Shares outstanding
9.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
67.7%
Return on Equity
-121.0%
ROCE
-233.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-363.3m | $-366.6m
EBIT
$-367.0m | $-370.0m
Net Income
$-2.4b | $-1.0b
Free Cash Flow
$-144.7m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-217.4% | -211.6%
EBIT
-211.0% | -205.3%
Net Income
-2,078.2% | -756.1%
Free Cash Flow
-44.8%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-366.6
FCF per Share
$-16.0
Short interest
10.8%
Employees
154
Rev per Employee
$0.0
Show more

Is Vor Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Vor Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

6x Buy
67%
3x Hold
33%

Analyst Opinions

9 Analysts have issued a Vor Biopharma Inc forecast:

Buy
67%
Hold
33%

Financial data from Vor Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 39 39
35% 35%
-
- Research and Development Expense 328 328
269% 269%
-
-363 -363
217% 217%
-
- Depreciation and Amortization 3.73 3.73
5% 5%
-
EBIT (Operating Income) EBIT -367 -367
211% 211%
-
Net Profit -2,450 -2,450
2,078% 2,078%
-

In millions USD.

Don't miss a Thing! We will send you all news about Vor Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vor Biopharma Inc Stock News

Neutral
GlobeNewsWire
11 days ago
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's ...
Neutral
GlobeNewsWire
20 days ago
BOSTON, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, announced today that it has entered into a securities purchase agreement to sell 13,876,032 shares of its common stock at a price of $10.81 per share to a select group of institutional and accredited healthcare specialist investors in a priva...
Neutral
GlobeNewsWire
about 2 months ago
Multiple Late-Stage Data Readouts Reinforce Telitacicept's Broad Potential Across Autoimmune Diseases Expansion of Executive Leadership and Board Strengthens Global Development Capabilities
More Vor Biopharma Inc News

Company Profile

Vor Biopharma, Inc. engages in developing cell therapies for treating cancer. It is a clinical-stage cell therapy company that combines a novel patient engineering approach with therapies to provide a single company solution for patients suffering from hematological malignancies. The company was founded by Aleks Radovic-Moreno and Siddhartha Mukherjee on December 30, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Bob Ang
Employees 154
Founded 2015
Website www.vorbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today